|Articles|April 15, 2019
- BioPharm International-04-15-2019
- Volume 2019 eBook
- Issue 1
Navigating the Biologics Wave
Author(s)Felicity Thomas
Contract manufacturing organizations need to adapt to successfully overcome the specific challenges posed by complex therapies.
Advertisement
The growth within the field of biologics has been palpable over the past few years and is expected to continue to expand for the foreseeable future. With such a positive outlook, outsourced capabilities may also be able to ride on the crest of the biologics wave, although as reported by Results Healthcare, contract manufacturing organizations (CMOs) may need to consider subsector patterns to take advantage of the market shifts.
BioPharm International spoke with Mike Danzi, CEO of Legacy Pharmaceuticals Switzerland, which is a SwissMedic and US FDA-approved CMO, about the challenges facing CMOs in the field of biologics and best practices for working with complex therapies.
Read
Article Details
BioPharm International
eBook: Outsourcing Resources 2019
April 2019
Pages: 20–21
Citation
When referring to this article, please cite it as F. Thomas, "Navigating the Biologics Wave," BioPharm International's Outsourcing Resources eBook (April 2019).
Articles in this issue
over 6 years ago
Complex and Customized: Manufacturing New Molecular Formatsover 6 years ago
Emerging Therapies Test Existing Bioanalytical MethodsNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
How Big Biopharma Investment in CGTs Will Redefine the Industry Pipeline
2
Report - Digital Transformation in Biopharma: The Gap Between Hype and Implementation
3
BioPharm Weekly News Roundup—Week of Oct. 6, 2025
4
Reducing CAR-T Manufacturing Times and Cost: Q&A with Trenchant’s Jon Ellis
5
